<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> have a poor prognosis and present a challenge to clinicians </plain></SENT>
<SENT sid="1" pm="."><plain>The role of the antiepidermal growth factor receptor (EGFR) pathway in tumorogenesis and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> has been well defined </plain></SENT>
<SENT sid="2" pm="."><plain>This paper will review the use of anti-EGFR monoclonal antibodies in the treatment of operable, as well as <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> both in the setting of KRAS mutation unselected patients and later in KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Active investigations designed to further identify predictive biomarkers that may be potentially druggable are reviewed as well </plain></SENT>
</text></document>